We're making three more trades, including the initiation of a household name

Jim Cramer’s Charitable Trust trimmed Eli Lilly, selling 10 shares at about $1,034 to reduce LLY weighting to ~2.5% (from 2.8%), locking roughly a 330% gain on 2022 purchases while downgrading the stock to a hold and raising the price target to $1,100 from $925; proceeds (and cash from an earlier Disney sale) are being redeployed into consumer names. The Trust bought 100 Nike shares at roughly $62 (increasing the position to 1,400 shares and a ~2.4% weighting) on conviction in CEO Elliott Hill’s “Win Now” turnaround, and initiated a 250‑share position in Procter & Gamble at about $146 (≈1% weighting) with a $165 price target. The P&G addition reflects a tactical shift into higher‑quality, defensive staples—P&G has 40 consecutive quarters of organic sales growth, a ~2.9% yield, 69 years of dividend increases and $5bn of planned buybacks—positioning the portfolio for a potential rotation out of high‑beta AI names into steadier consumer franchises.

Analysis

Jim Cramer’s Charitable Trust trimmed Eli Lilly by selling 10 shares at roughly $1,034 each, lowering the position to about 90 shares and a weighting of ~2.5% from 2.8%, thereby locking an approximately 330% gain on 2022 purchases. The trust simultaneously downgraded LLY to a 2 rating even as it raised its price target to $1,100 from $925, citing a 55% rally since Aug. 13 and a parabolic move that pushed market capitalization near $1 trillion — rationale focused on disciplined profit-taking amid outsized recent appreciation.

The trust redeployed proceeds (and cash from an earlier Disney sale) into consumer names, buying 100 Nike shares at roughly $62 to bring the NKE stake to 1,400 shares (2.4% weighting) and initiating a 250-share position in Procter & Gamble at about $146 (~1% weighting). Nike exposure reflects conviction in CEO Elliott Hill’s “Win Now” turnaround after a recent volatile intraday swing, while P&G was chosen as a higher-quality defensive alternative to Kimberly-Clark amid sector underperformance.

Procter & Gamble’s initiation is grounded in company fundamentals cited in the note: 40 consecutive quarters of organic sales growth, a run toward a 10th straight year of core EPS growth, a ~2.9% dividend yield with 69 years of increases, and $5 billion of planned buybacks; shares are ~12% YTD down and made a 52-week low of $145.50 on Nov. 11. The trades signal a tactical tilt from high-beta growth names into steadier consumer franchises while de-risking a parabolic winner, but they also introduce execution risk on Nike’s turnaround and require monitoring whether the market rotates back into staples as expected.

Key Decisions for Investors

• Consider trimming outsized winners after parabolic rallies as Cramer did with LLY — realize gains and reduce weighting while monitoring the upgraded $1,100 target for further valuation context
• Add selectively to Nike on weakness if conviction in Elliott Hill’s ‘Win Now’ execution remains intact, using recent ~$62 entry (and the prior ~$64 buy) as a reference for incremental buys while watching near-term volatility
• Initiate or modestly increase exposure to high-quality staples like Procter & Gamble for defensive earnings durability given its 40-quarter organic growth streak, 69-year dividend increase history, ~2.9% yield and $5bn buyback plan, buying on continued weakness toward recent lows
• Monitor catalysts that could invalidate the rotation thesis — specifically Nike execution metrics and whether staples begin to re-rate; be prepared to trim or hedge if the market does not rotate out of high-beta names